Evidence map›Paper›PMID 40671226›Full record

ReviewCurrent neuropharmacology2026

Venlafaxine and Delirium: Understanding the Association.

Francisco Epelde

Abstract readReview
In one paragraph

Review in Current neuropharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Francisco EpeldeInternal Medicine Department, Parc Taulí Hospital Universitari, Institut d'Investigació iInnovació Parc Taulí (I3PTCERCA), Universitat Autònoma de Barcelona, Sabadell, Spain.ORCID 0000-0001-5547-4025

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Delirium represents a significant clinical, economic, and societal challenge, frequently arising in hospitalized patients due to multiple factors, including pharmacological triggers. Recognizing and preventing delirium is crucial to improving patient outcomes and reducing healthcare costs. This review focuses on the association between venlafaxine, a commonly used antidepressant, and delirium. We explore potential mechanisms, clinical presentations, and risk factors linked to venlafaxine-induced delirium, emphasizing the need for heightened awareness among clinicians. The findings underscore the importance of vigilance during drug initiation, dosage adjustment, or withdrawal to mitigate the risk of this neuropsychiatric condition.

Indexed as

Antidepressive Agents, Second-GenerationDeliriumVenlafaxine HydrochlorideAnimalsHumansAntidepressive Agents, Second-GenerationVenlafaxine HydrochlorideAnticholinergic deliriumantidepressantsgeriatric medicineneuropsychiatric conditiontoxic deliriumvenlafaxine

Identifiers

PMID40671226
PMCPMC13519564

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.